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Abstract
Objectives: Urethral injection of botulinum A toxin (BoNT-A) has thera-
peutic effects on voiding dysfunction. However, the optimal dose remains 
to be determined. This study compared the therapeutic results of urethral 
injections of 50 U and 100 U of BoNT-A.
Materials and Methods: Sixty-six patients with voiding dysfunction were 
randomly treated with urethral injections of 50 U (n = 33) or 100 U (n = 33) 
of BoNT-A (BOTOX). The therapeutic results and changes in the urody-
namic parameters were compared between these two groups of patients.
Results: The overall therapeutic results in the 100 U and 50 U injection 
groups were excellent in 20 (60.6%) and 23 (69.7%) patients, improved 
in 10 (30.3%) and 5 (15.2%), and failed in 3 (9%) and 5 (15.2%), respec-
tively. Significant reductions in the voiding pressure, postvoid residual 
volume, and maximal urethral closure pressure as well as improvement 
in the quality of life index and increases in the maximum flow rate were 
noted after treatment in both groups. No significant between-group differ-
ences were noted in the net changes of the urodynamic parameters after 
treatment. Excellent results were noted in 68% and 33% of patients with 
detrusor underactivity, and in 71.4% and 70.8% of patients with hyperac-
tive urethral sphincter who received injections of 50 U and 100 U, respec-
tively. The mean durations of therapeutic effect were 6.4 ± 3.6 months and 
8.4 ± 3.4 months in the 50 U and 100 U groups, respectively (p = 0.022).
Conclusion: Urethral injection of 50 U of BOTOX is as effective as 100 U 
in the treatment of voiding dysfunction of any etiology, but the duration 
of therapeutic effect was significantly shorter in the group who received 
50 U. [Tzu Chi Med J 2007;19(3):134–138]
available at http://health.elsevier.com/tcmj
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1. Introduction
Botulinum A toxin (BoNT-A) has been demonstrated 
to relieve urethral resistance by paralyzing the urethral 
sphincter [1]. A good therapeutic effect has been 
observed in patients with detrusor sphincter dyssyn-
ergia, spastic urethral sphincter, and isolated urethral 
sphincter obstruction [2,3]. Patients with spinal cord 
lesions, chronic stroke, and detrusor underactivity 
due to previous radical hysterectomy can also benefit 
from this treatment [4–6].
In previous studies, most treatments were single 
injections of 100 U of BoNT-A [1,2,4–6]. Only one 
reported study used 50 U to treat patients with detru-
sor underactivity and voiding dysfunction [7]. There 
is no consensus on the appropriate dose of BoNT-A 
for treating specific diseases or specific urethral con-
ditions in patients with voiding dysfunction. In the 
treatment of anal fissure, a small dose of 20–50 U of 
BoNT-A has been adequate to achieve a successful 
result [8,9]. Repeat treatments with a dose of BoNT-A 
less than 1.5 U/kg have been shown to facilitate relief 
of contracture in extremities due to muscle spasm 
[10]. In the treatment of voiding dysfunction of vari-
ous etiologies, the optimal dose of BoNT-A remains 
to be determined.
This randomized study was designed to compare 
the relative efficacy of the two most widely used doses 
of BoNT-A for the treatment of voiding dysfunction of 
different etiologies. The results of this study will pro-
vide clinical evidence to substantiate dose selection 
of BoNT-A in these patients.
2. Materials and methods
Sixty-six patients with voiding dysfunction who had 
failed treatment with conventional medications were 
enrolled in this randomized study. Patients were ran-
domly assigned to receive either 50 U or 100 U of 
BoNT-A (BOTOX; Allergan, Inc., Irvan, CA, USA) regard-
less of the etiology of voiding dysfunction.
Upon enrolment, baseline screening was performed 
in all patients, including a videourodynamic study to 
confirm bladder and urethral dysfunction. The patients 
were then classified on the basis of videourody-
namic results into the following categories: detrusor 
sphincter dyssynergia (DSD), dysfunctional voiding, 
poor relaxation of the urethral sphincter, or detru-
sor underactivity with non-relaxation of the urethral 
sphincter. Urethral pressure profilometry was also 
performed in all patients at the baseline screening. 
During urethral pressure profilometry, the infusion 
rate was 4 mL/min and the puller speed was set at 
1 mm/sec. The maximal urethral closure pressure 
(MUCP) and functional profile length (FPL) were meas-
ured. Parameters assessed during videourodynamic 
study included the maximum flow rate (Qmax), 
detrusor pressure at Qmax (Pdet), voided volume and 
postvoid residual (PVR). The definitions of the termi-
nology used to describe these urodynamic studies 
were in accordance with the recommendations of the 
International Continence Society [11]. The quality of 
life (QoL) index (scored from 0 to 6, representing 
excellent to bad) for voiding dysfunction was also 
assessed according to the international prostatic 
symptom score (IPSS) system [12].
This study was approved by the institutional review 
board of the hospital. Before treatment, each patient 
was thoroughly informed about the procedures, and 
written informed consent was obtained. Information 
conveyed to patients included possible complications 
associated with the injection of BoNT-A, such as ana-
phylaxis, hematuria, micturition pain, acute or chronic 
urinary retention, and urinary tract infections.
Urethral BoNT-A injection was performed in the 
operating room under light intravenous general 
anesthesia. Patients were placed in the lithotomy posi-
tion. After sterilization and draping, the BoNT-A solu-
tion was injected directly into the urethral sphincter 
under cystoscopic guidance in men at the 3, 6, 9 and 
12 o’clock positions at a depth of about 5 mm, and 
transcutaneously and periurethrally in women at an 
injection depth of 15 mm. Each vial of 100 U BoNT-A 
was diluted in 8 mL of normal saline. For patients 
who received 50 U of BoNT-A, the 4 mL BoNT-A solu-
tion was further diluted to a volume of 8 mL. Thus, 
both groups of patients received the same injection 
volume but different doses of BoNT-A.
After urethral injection, a 14-Fr Foley catheter was 
routinely placed overnight. Patients were discharged 
the next morning and then followed-up in the outpa-
tient department 2 weeks later and monthly there-
after. Prophylactic antibiotics were prescribed for 
1 week postoperatively. Other medications such as 
α-adrenergic blockers and skeletal muscle relaxants 
were not used concomitantly.
Qmax and PVR were routinely checked at each 
follow-up visit. Urethral pressure profilometry and vid-
eourodynamic study were repeated at the 1-month 
follow-up. Data for variables including the MUCP, FPL, 
Pdet, Qmax, and PVR were recorded.
The patient was interviewed to determine voiding 
conditions after BoNT-A injection and the QoL index 
was assessed by a questionnaire. An excellent result 
was defined as a ≥ 2 improvement in the QoL index 
in combination with a ≥ 50% reduction in PVR and 
a ≥ 25% reduction in MUCP. An improved result was 
defined as an improvement in the QoL of 1 com-
bined with improvement in urodynamic parameters as 
shown by either a ≥ 50% reduction in PVR or a ≥ 25% 
reduction in MUCP. Treatment was defined as failed 
if there was no improvement in QoL regardless of the 
urodynamic improvement.
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The primary endpoint was set at 1 month after treat-
ment and the therapeutic outcomes were assessed. 
Patients were then followed-up at the outpatient clinic 
regularly. The duration of therapeutic effect was deter-
mined by the length of time between treatment and 
the return of voiding symptoms to baseline.
The therapeutic results in patients who received 
50 U and 100 U injections of BoNT-A were compared. 
Urodynamic parameters at baseline were compared 
with those after urethral BoNT-A treatment in each 
group of patients. The net changes in these urody-
namic parameters were also compared between the 
two groups of patients. The patients were further sub-
grouped according to voiding dysfunction etiology, 
and the therapeutic results in these subgroups were 
analyzed according to whether the patients received 
50 U or 100 U of BoNT-A. Based on these results, the 
optimal dose of BoNT-A for urethral injection in spe-
cific voiding dysfunction categories was proposed 
for clinical reference.
Statistical analyses were performed using paired t 
test, non-parametric statistics by χ2 test and ANOVA. 
A p value of less than 0.05 was considered statisti-
cally significant.
3. Results
A total of 66 patients were enrolled in this study, and 
received urethral BoNT-A injection at a dose of either 
50 units (n = 33) or 100 units (n = 33). All patients had 
previously failed treatment with medications such as 
α-blockers and skeletal muscle relaxants.
In order to test the therapeutic effects of the doses, 
the initial 16 patients were not randomized in this study. 
Ten patients with detrusor underactivity were treated 
with 50 U of BoNT-A, whereas 6 with dysfunctional 
voiding were treated with 100 U of BoNT-A. After that, 
the remaining 50 patients were randomly assigned to 
receive 50 U or 100 U of BoNT-A irrespective of the eti-
ology of voiding dysfunction. Five and 6 patients with 
poor relaxation of the urethral sphincter, 19 and 9 with 
detrusor underactivity, 6 and 15 with dysfunctional 
voiding, and 3 and 3 with DSD received 50 U and 100 U 
of BoNT-A, respectively. In the 50 U treatment group, 
18 patients were women and 15 were men, whereas 
in the 100 U treatment group, 19 patients were women 
and 14 were men (p > 0.05). The mean ages were 
64.8 ± 17.1 years and 60.0 ± 14.6 years in the 50 U and 
100 U treatment groups, respectively (p > 0.05).
The overall therapeutic results in the 50 U and 
100 U treatment groups showed that 23 (69.7%) and 
20 (60.6%) patients had excellent results, 5 (15.2%) 
and 10 (30.3%) patients had improved results, and 
5 (15.2%) and 3 (9.1%) patients had failed results, 
respectively (Fig. 1). The overall rates of successful 
treatment were 84.9% in the patients receiving 50 U 
and 90.9% in the patients receiving 100 U of BoNT-A 
(p = 0.452).
Table 1 shows the urodynamic parameters at base-
line and after BoNT-A treatment in all patients. A sig-
nificant reduction in Pdet, PVR, MUCP and QoL index, 
and a significant increase in Qmax were noted in both 
groups. However, the net changes in these outcome 
parameters after BoNT-A treatment were not signifi-
cantly different between groups.
Table 1 — Changes in urodynamic parameters and quality of life index in patients who received urethral injections 
of 50 units or 100 units of botulinum A toxin
 MUCP (cmH2O) FPL (cm) Pdet (cmH2O) Qmax (mL/s) PVR (mL) QoL index
50 U (n = 33) 66.6 ± 34.4 3.3 ± 0.5 51.6 ± 40.7 5.6 ± 5.3 285 ± 154  4.1 ± 0.9
 48.9 ± 27.3 3.1 ± 0.3 37.5 ± 35.4 8.3 ± 5.4 120 ± 145 1.9 ± 1.2
 p < 0.001 p = 0.186 p < 0.001 p = 0.016 p < 0.001 p  < 0.001
100 U (n = 33) 61.9 ± 26.0 3.8 ± 1.0 53.8 ± 38.9  5.8 ± 4.8 261 ± 157  4.0 ± 1.0
 49.5 ± 21.5 4.1 ± 1.0 33.0 ± 31.7 10.5 ± 5.9 114 ± 107  2.2 ± 1.2
 p = 0.049 p = 0.493 p = 0.006 p < 0.001 p < 0.001  p < 0.001
MUCP = maximal urethral closure pressure; FPL = functional profile length; Pdet = detrusor pressure at Qmax; Qmax = maximum flow rate; 
PVR = postvoid residual; QoL = quality of life.
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Fig. 1 — Therapeutic results of patients receiving urethral 
injection of 50 units or 100 units of botulinum A toxin.
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Among the 28 patients with detrusor underactivity, 
an excellent result was noted in 13 (68.4%) patients 
after 50 U injection compared to 3 (33%) patients in the 
100 U group (p = 0.066). Among the 21 patients with 
dysfunctional voiding, excellent results were found in 
5 (83.3%) patients in the 50 U group and 8 (53.3%) in 
the 100 U group (p = 0.399). Among the 6 patients with 
DSD, 2 (66.77%) and 3 (100%) patients had excellent 
results in the 50 U and 100 U injection groups, respec-
tively (p = 0.273). Among the 11 patients with poor 
relaxation of the urethral sphincter, 3 (60%) and 6 
(100%) patients had excellent results in the 50 U and 
100 U groups, respectively (p = 0.182). Combining the 
data from the latter three etiology groups, an excel-
lent result was noted in 10/14 (71.4%) and 17/24 
(70.8%) patients in the 50 U and 100 U groups, respec-
tively (p > 0.05). The overall rate of excellent results 
was 57.1% (16/28) and 71.1% (27/38) in patients 
with detrusor underactivity and hyperactive urethral 
sphincter, respectively (p = 0.515) (Table 2).
Treatment was classified as failed in 8 patients, 
including 5 who received 50 U and 3 who received 
100 U of BoNT-A. According to the patients, the maxi-
mum effect of urethral BoNT-A injection was reached 
at about 2 weeks after treatment and lasted from 5 
months to more than 12 months. Five patients with 
detrusor underactivity had recovery of detrusor con-
tractility after urethral BoNT-A injection and the effects 
lasted for more than 12 months without relapse of 
difficult urination. The mean duration of therapeutic 
effect was 6.4 ± 3.6 months and 8.4 ± 3.4 months in 
the 50 U and 100 U groups, respectively (p = 0.022).
4. Discussion
Urethral BoNT-A injection is effective in reducing ure-
thral resistance and facilitating spontaneous voiding. 
This treatment allows patients with spinal cord lesions 
and DSD to resume spontaneous voiding and abol-
ishes the complications of autonomic dysreflexia. In 
patients with dysfunctional voiding, BoNT-A injection 
can paralyze the spastic urethral sphincter and thereby 
improve voiding efficiency as well as irritative bladder 
symptoms after treatment [3]. Patients with detrusor 
underactivity and a fixed urethral resistance can also 
resume spontaneous voiding by abdominal straining 
after treatment [7]. These therapeutic effects of BoNT-A 
urethral injections can reduce the frequency of clean 
intermittent catheterization and even allow freedom 
from indwelling Foley catheter use [4,7]. The quality of 
life of patients treated with urethral BoNT-A injection 
can be significantly improved [3,4]. Although stress uri-
nary incontinence may be a problem for women with 
detrusor underactivity and low bladder compliance, 
especially at night, most patients can enjoy a better 
quality of life with easy voiding after treatment.
Although urethral BoNT-A injection has been dem-
onstrated to have good therapeutic effects, not all 
patients with voiding dysfunction benefit from this 
treatment. A small group of patients still cannot 
resume spontaneous voiding after treatment. The 
causes for failed treatment in these patients may 
include psychological inhibition, poor cortical facilita-
tion, or severe urethral sphincter spasticity in patients 
with DSD or dysfunctional voiding [3]. Repeat urethral 
injections may achieve a better therapeutic result in 
these patients. However, the cost-effectiveness should 
also be considered.
Although there was a disproportional distribution 
of different etiologies of voiding dysfunction in the 
50 U and 100 U treatment groups, this study demon-
strated that urethral injection of 50 U of BoNT-A is as 
effective as 100 U in treating voiding dysfunction of 
various etiologies. The rate of excellent results in the 
50 U group (69.7%) was similar to that in the 100 U 
group (60.6%).
In patients with detrusor underactivity, the rate of 
successful treatment as defined by an excellent result 
was significantly better in the 50 U group than in the 
100 U group. This result might have been due to the 
greater percentage of women with detrusor underac-
tivity in the 50 U group. Women with detrusor under-
activity in this study could all void with increased 
abdominal pressure after urethral BoNT-A injection, 
indicating excellent therapeutic results with a small 
dose of BoNT-A. On the contrary, a higher percent-
age of patients with hyperactive urethral sphincter 
(DSD, dysfunctional voiding, poor relaxation of ure-
thral sphincter) were included in the 100 U group and 
the therapeutic result was therefore slightly affected. 
Table 2 — Therapeutic results of different doses of ure-
thral botulinum A toxin injections in patients with dif-
ferent etiologies of voiding dysfunction
 Excellent Improved Failed p
PRS (n = 11)     0.182
 50 U (5) 3 (60%) 2 (40%) 0
 100 U (6) 6 (100%) 0
DU (n = 28)     0.066
 50 U (19) 13 (68.4%) 2 (10.5%) 4 (21.1%)
 100 U (9) 3 (33.3%) 5 (55.6%) 1 (11.1%)
DV (n = 21)     0.399
 50 U (6) 5 (83.3%) 1 (16.7%) 0
 100 U (15) 8 (53.3%) 5 (33.3%) 2 (13.3%)
DSD (n = 6)     0.273
 50 U (3) 2 (66.7%) 0 1 (33.3%)
 100 U (3) 3 (100%) 0 0
Detrusor 16 (57.1%) 7 (25%) 5 (17.9%) 0.515
 underactivity
 (n = 28)
Hyperactive 27 (71.1%) 8 (21.1%) 3 (7.9%)
 sphincter
 (n = 38)
PRS = poor relaxation of urethral sphincter; DU = detrusor underactiv-
ity; DV = dysfunctional voiding; DSD = detrusor sphincter dyssynergia.
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Nevertheless, the overall success rate in both groups 
of patients showed no significant difference.
There was a lower rate of excellent results and 
a higher rate of failed results in the patients with 
detrusor underactivity than in those with sphincter 
hyperactivity. Although the overall statistical analysis 
revealed no significant difference between these two 
groups, the result might have some clinical implica-
tions. Patients with detrusor underactivity and void-
ing dysfunction need abdominal straining to void 
even if their urethral sphincters have been paralyzed 
by injection of BoNT-A. Therefore, in patients who 
cannot properly use abdominal pressure to void, such 
as those with multiple strokes, general weakness, or 
those who are bedridden, spontaneous voiding might 
not be possible after urethral BoNT-A treatment.
Voiding dysfunction is a graded pathological con-
dition. Mild to moderate improvement after urethral 
BoNT-A injection might not significantly improve 
quality of life. In this study, the QoL index was used 
to measure subjective improvement, and a ≥ 25% 
reduction in MUCP and a ≥ 50% reduction in PVR were 
used to measure objective improvement. If the QoL 
index improved by 1, the result was only considered 
improved. These results demonstrated that urethral 
BoNT-A injection with 50 U is adequate for treating 
patients with voiding dysfunction resulting from poor 
relaxation of the urethral sphincter or dysfunctional 
voiding, and for some patients with DSD or detru-
sor underactivity. The use of 100 U of BoNT-A did not 
result in a higher rate of success in treating voiding 
dysfunction of any etiology. However, the duration 
of therapeutic effect was significantly longer in the 
100 U treatment group than in the 50 U treatment 
group, suggesting that a higher dose of BoNT-A might 
induce a greater denervation effect. For patients who 
have failed initial BoNT-A treatment, repeat treatment 
after the first month can be instituted. Although the 
patients in this study did not receive repeat treat-
ment, it is reasonable to consider repeat treatment 
with an increased dose of BoNT-A for patients with 
severe urethral hyperactivity, such as patients with 
DSD or dysfunctional voiding, who fail the initial low-
dose treatment.
This study has shown that BoNT-A urethral injec-
tion at a dose of 50 U is as effective as 100 U in the 
treatment of voiding dysfunction of any etiology. The 
duration of therapeutic effect was significantly shorter 
in the 50 U group, suggesting that greater denerva-
tion is achieved with a larger dose of BoNT-A. A dose 
of 50 U of BoNT-A is appropriate for urethral injection 
for initial treatment of voiding dysfunction refractory 
to conventional medication.
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